I

InflaRx NV
D

IFRX

0.85650
USD
0.04
(4.66%)
مغلق
حجم التداول
2,184
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
58,025,417
أصول ذات صلة
A
AMRN
0.600
(3.98%)
15.690 USD
C
CRBP
-0.26000
(-2.72%)
9.31000 USD
M
MTNB
0.69200
(42.07%)
2.33700 USD
V
VKTX
-0.230
(-0.57%)
40.030 USD
المزيد
الأخبار المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.